Vancouver, British Columbia--(Newsfile Corp. - October 22, 2018) - Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a
Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade
formulations of cannabinoids, has filed an application to become a Licensed Producer under the Access to Cannabis for Medical
Purposes Regulations with Health Canada. The License, if granted by Health Canada, would allow the company to process cannabis
products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new
purpose-built facility.
InvestmentPitch Media has produced a "video" which provides a brief overview of this news. If this link is not enabled, please visit
www.InvestmentPitch.com and enter "Canntab" in
the search box.
Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. The company's
patented technology focuses on the delivery of standardized medical cannabis extract, from selective strains, allowing medical
professionals to provide pharmaceutical dosages to deliver therapeutic treatments to their patients.
Jeff Renwick, CEO of CannTab, stated: "We are excited to announce, as we enter into a new era of legalization, that Canntab
has submitted its application to Health Canada to become a Licensed Producer. This is another step that enables Canntab to further
diversify its manufacturing and distribution capabilities towards a world-wide rollout of its suite of precision oral dose delivery
platforms for cannabis-based products."
Canntab recently signed a non-binding Letter of Intent with NewCanna S.A.S. of Bogota, Colombia. The LOI establishes a
significant bi-lateral relationship granting NewCanna the right to sell and distribute certain Canntab exclusive proprietary
products, and the right to utilize Canntab's know-how and patents in the countries of Colombia, Chile, Paraguay and Spain.
The two parties have a 60-day period to complete a formal agreement, which will trigger a one-time, non-refundable License Fee
of US $2-million payable to Canntab by NewCanna in consideration for the exclusive license to be granted by Canntab to NewCanna.
NewCanna would become a key supplier of raw materials for Canntab and on a cost basis which will be very favourable in comparison
to other sources worldwide.
For more information, please visit the company's website at www.canntab.ca, contact Richard Goldstein, CFO, at 416-957-6303 or email info@canntab.ca.
About InvestmentPitch Media
InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story
ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing
short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com
